Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Elektrofi","sponsor":"Argenx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Elektrofi Enters Global Collaboration and License Agreement with argenx to Explore New Subcutaneous Product Formulations","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III"},{"orgOrder":0,"company":"Elektrofi","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$470.0 million","upfrontCash":"$20.0 million","newsHeadline":"Elektrofi and Lilly Enter Multi-Target Research Collaboration and License Agreement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery"},{"orgOrder":0,"company":"Elektrofi","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"D","amount":"$793.0 million","upfrontCash":"$18.0 million","newsHeadline":"Elektrofi and Janssen Biotech Enter Worldwide Collaboration and License Agreement to Exclusively Develop up to Five Programs Utilizing Elektrofi's Formulation Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Elektrofi

    Menu

    Elektrofi

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Elektrofi

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Elektrofi and Janssen Biotech Enter Worldwide Collaboration and License Agreement to Exclusively Develop up to Five Programs Utilizing Elektrofi's Formulation Technology

              Details:

              The collaboration will initially focus on developing an at home self-administered subcutaneous version of a lead oncology asset, and up to four additional targets using Elektrofi's innovative formulation technology platform.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: JANSSEN BIOTECH

              Deal Size: $793.0 million Upfront Cash: $18.0 million

              Deal Type: Collaboration January 03, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Elektrofi

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Elektrofi and Lilly Enter Multi-Target Research Collaboration and License Agreement

              Details:

              The agreement aims to develop next-generation medicines that can be delivered subcutaneously by using Elektrofi’s ultra-high concentration microparticle suspension technology platform.

              Lead Product(s): Undisclosed

              Therapeutic Area: Immunology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Eli Lilly

              Deal Size: $470.0 million Upfront Cash: $20.0 million

              Deal Type: Licensing Agreement October 24, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Elektrofi

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Elektrofi Enters Global Collaboration and License Agreement with argenx to Explore New Subcutaneous Product Formulations

              Details:

              Under the terms of this collaboration and license agreement, Argenx and Elektrofi will explore new subcutaneous formulations for therapeutic products directed at the human neonatal Fc receptor (FcRn), including efgartigimod, and up to one additional target.

              Lead Product(s): Efgartigimod

              Therapeutic Area: Immunology Product Name: ARGX-113

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Argenx

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration April 20, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY